article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

article thumbnail

Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine

The Pharma Data

Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

The Pharma Data

1 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

article thumbnail

FDA Approves First Generic of Symbicort to Treat Asthma and COPD

The Pharma Data

This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing).

article thumbnail

Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe

The Pharma Data

Sandoz is the global leader in generic antibiotics and operates the only vertically-integrated antibiotic network left in Europe, despite fierce competition from Asia. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

article thumbnail

Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine | Novartis

The Pharma Data

Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

article thumbnail

New Sandoz Board of Directors appointed

The Pharma Data

For more information on the Sandoz Board of Directors, please also see [link] Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Our ambition is to be the world’s leading and most valued generics company.

Sales 40